Search results
Results from the WOW.Com Content Network
[citation needed] Risk factors include polycystic ovary syndrome, young age, low BMI, high antral follicle count, the development of many ovarian follicles under stimulation, extreme elevated serum estradiol concentrations, the use of hCG for final oocyte maturation and/or release, the continued use of hCG for luteal support, and the occurrence ...
For other stimulation protocols, the evidence around pretreatment with combined oral contraceptives and progesterone only is uncertain. [23] Findings are conflicting, but metformin treatment as a complement in IVF cycles may reduce the risk of ovarian hyperstimulation syndrome and increase live birth rates. [24]
Initial evaluation during diagnosis aims at determining pregnancy status, menopausal status, and the source of bleeding. One definition for diagnosing the condition is bleeding lasting more than 7 days or the loss of more than 80 mL of blood heavy flow. [3] Treatment depends on the cause, severity, and interference with quality of life. [4]
OHSS is a potential side effect of stimulating the ovaries to produce multiple eggs at the same time either during the first part of an IVF cycle or when planning to freeze eggs, reproductive ...
The actress turned beauty entrepreneur has relaunched her Flawless by Gabrielle Union haircare line on Amazon today, with products ranging between $4-$10.
Other options include topical or systemic spironolactone or flutamide, although they have a high incidence of feminising side effects and are better tolerated in female androgenic hair loss. More advanced cases may be resistant or unresponsive to medical therapy, however, and require hair transplantation .
Hair loss is a well-known side effect of many chemotherapy drugs used to treat certain forms of cancer. Similar to other toxins that cause hair loss, hair loss from cancer medications usually isn ...
There are no side-effects such as ovarian hyperstimulation syndrome (OHSS), bloating, mood changes or other concerns relating to ovarian stimulation. Due to the effect of ovarian stimulation drugs on the body, patients undergoing stimulation cannot pursue consecutive cycles of treatment and need to take 2–3 months break between treatment cycles.